$12.8 Billion Prostate Cancer Markets: Global Drug Forecast and Market Analysis to 2028 - ResearchAndMarkets.com

DUBLIN--()--The "Prostate Cancer: Global Drug Forecast and Market Analysis to 2028" report has been added to ResearchAndMarkets.com's offering.

The prostate cancer market will undergo a moderate increase at a compound annual growth rate (CAGR) of 3.3% from an estimated $9.3bn in 2018 to $12.8bn in 2028 in the eight major markets (8MM - US, France, Germany, Italy, Spain, UK, Japan and China.

The report Prostate Cancer: Global Drug Forecast and Market Analysis to 2028 provides an overview of the risk factors, comorbidities, and global and historical trends for prostate cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).

The main drivers of growth will be an aging population, continued uptake of second-generation hormonal agents in the metastatic hormone nave (mHNPC) and non-metastatic castration resistant (nmCRPC) prostate cancer settings, and the launch and uptake of 13 new premium-priced therapies, including the newly approved Nubeqa (darolutamide).

Of these, the biggest driver of growth is the expansion of second-generation hormonal agents into metastatic hormone-naive prostate cancer (mHNPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC), which will bring these expensive drugs into earlier lines of therapy.

This will doubly impact market growth, as the shifting paradigm will create space in the metastatic castration-resistant prostate cancer (mCRPC) space, where these agents once reigned, allowing pipeline agents a chance to gain substantial market share and fill this void.

Second-generation hormonal therapies Johnson & Johnson's Zytiga (abiraterone acetate) and Erleada (apalutamide), Astellas/Pfizer's Xtandi (enzalutamide) and Bayer/Orion's Nubeqa (darolutamide) have been racing to acquire approvals and label expansions over the past couple years.

Between 2018 and 2019, three of these agents gained approval in nmCRPC. Zytiga gained a label expansion for metastatic hormone-naive prostate cancer (mHNPC) in 2017 for the EU and in 2018 for the US, while the other three agents are soon to follow. J&J filed for US Food and Drug Administration (FDA) approval of Erleada in mHNPC in April 2019, and Xtandi was given an FDA priority review in August.

Scope

  • Overview of prostate cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized prostate cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven patient segments, forecast from 2018 to 2028.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the prostate cancer therapeutics market.
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for prostate cancer. The most promising candidates in Phase III development are profiled.
  • Analysis of the current and future market competition in the global prostate cancer market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Topics Covered:

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Prostate Cancer: Executive Summary

2.1 Prostate Cancer Market Expected to Increase Despite Generic Abiraterone Entry

2.2 Big Pharma Brands Enter the Prostate Cancer Market Using Combination Strategies for mCRPC

2.3 Unmet Need Will Remain for the Identification of New Targets and Biomarkers of Response

2.4 Prostate Cancer Pipeline Moving Towards Precision Medicine

2.5 What Do the Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

3.3 Upcoming Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.1.3 Biomarkers

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods, Population

5.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer

5.4.4 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Gleason Scores

5.4.5 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis

5.4.6 Forecast Assumptions and Methods, Diagnosed Incident Cases of Prostate Cancer by Risk Category

5.4.7 Forecast Assumptions and Methods, Metastatic Cases at Diagnosis

5.4.8 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Prostate Cancer

5.4.9 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases (Metastatic and Non-Metastatic) that Progress from Hormone-Sensitive Disease to CRPC by Status

5.5 Epidemiological Forecast for Prostate Cancer (2018-2028)

5.5.1 Diagnosed Incident Cases of Prostate Cancer

5.5.2 Age-Specific Incident Cases of Prostate Cancer

5.5.3 Diagnosed Incident Cases of Prostate Cancer by Gleason Score

5.5.4 Diagnosed Incident Cases of Prostate Cancer by Stage at Diagnosis

5.5.5 Diagnosed Incident Cases of Prostate Cancer by Risk Category

5.5.6 Metastatic Cases at Diagnosis

5.5.7 Five-Year Diagnosed Prevalent Cases of Prostate Cancer

5.5.8 Diagnosed Five-Year Prevalent Cases of Prostate Cancer that Progress from Hormone-Sensitive Disease to CRPC by Status

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Disease Management

6.1 Diagnosis and Treatment Overview

6.2 Treatment Overview

6.2.1 Treatment Guidelines and Leading Prescribed Drugs

6.2.2 Clinical Practice

6.3 US

6.4 France

6.5 Germany

6.6 Italy

6.7 Spain

6.8 UK

6.9 Japan

6.10 China

7 Competitive Assessment

7.1 Overview

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Therapies with a Durable OS Benefit or Cure for mCRPC

8.3 Identification of New Targets and Positive Predictive Biomarkers of Response

8.4 Advancements in the Detection and Treatment of Drug Resistance

8.5 Therapeutic Options for nmCRPC

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Company Profiles

10.3.1 Johnson & Johnson

10.3.2 Astellas

10.3.3 AstraZeneca

10.3.4 Bayer

10.3.5 Clovis Oncology

10.3.6 Merck

10.3.7 Novartis

10.3.8 Pfizer

10.3.9 Roche

10.3.10 Sanofi

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers - Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

11.5 China (Urban)

11.5.1 Forecast

11.5.2 Key Events

11.5.3 Drivers and Barriers

12 Appendix

Companies Mentioned

  • AbbVie
  • Advanced Accelerator Applications
  • Advantagene
  • Allergan
  • Astellas
  • AstraZeneca
  • Bayer
  • Clovis Oncology
  • Dendreon
  • Endo Pharmaceuticals
  • Endocyte
  • Ferring Pharmaceuticals
  • Genzyme
  • GlaxoSmithKline
  • Hinova
  • Ipsen
  • Janssen/J&J
  • Merck & Co.
  • Myovant Sciences
  • Novartis
  • Orion
  • Pfizer
  • Roche
  • Sanofi
  • Sotio
  • Takeda
  • TerSera Therapeutics
  • Tesaro
  • Tolmar

For more information about this report visit https://www.researchandmarkets.com/r/6jvh1v

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900